Drug intelligence / Profile preview

Nicoflex

Development stage
Unknown
Lead developer
Medimpex
Modality
Small Molecules
Administration
Topical
01

Overview

Nicoflex is a topical combination ointment developed by Medimpex for the treatment of musculoskeletal conditions. It contains three active ingredients: capsaicin, ethyl nicotinate, and ethylene glycol salicylate. Capsaicin acts as a counter-irritant by depleting substance P from sensory neurons; ethyl nicotinate serves as a vasodilator to improve local blood flow and absorption; and ethylene glycol salicylate provides analgesic and anti-inflammatory effects. The product is indicated for the relief of pain associated with bruises, sprains, arthrosis, myalgia, neuralgia, and sciatica, and is frequently used by athletes for muscle warm-up. Originally authorized in Hungary in 1978, the product is currently manufactured by Egis Pharmaceuticals following its acquisition of Medimpex's pharmaceutical operations.

Brand names
NicoflexNicoflex-Medimpex
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TRPV1 (Transient receptor potential cation channel subfamily V member 1)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Nicoflex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicoflex.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call